Trial Profile

Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA in Patients With Selected Resectable Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adjuvanted imsapepimut and etimupepimut (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Malignant melanoma; Mouth neoplasm; Oropharyngeal cancer; Skin cancer; Solid tumours; Squamous cell cancer
Focus Proof of concept; Therapeutic Use
Sponsors IO Biotech

Most Recent Events

04 Mar 2025 According to an IO Biotech media release, The company expects initial data from this trial in the second half of 2025.
09 Jan 2025 According to an IO Biotech media release, initial data from this trial is expected in 2025
09 Jan 2025 Status changed from recruiting to active, no longer recruiting as per IO Biotech media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com